At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
Pure PRP II +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Bone Marrow Aspirate Concentrate Compared With Platelet Rich Plasma for the Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Controlled Clinical Trial
In Brief
A Phase 4 clinical trial evaluating Pure PRP II and PureBMC for Knee Osteoarthritis. Completed, enrolled 90 participants across 1 site.
Detailed Summary
This study is intended to compare whether bone marrow aspirate concentrate or platelet rich plasma injections is more effective in treating knee osteoarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Osteoarthritis
CountriesUnited States
CollaboratorsEmCyte Corporation, BioSciences Research Associates, Inc
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedSep 2017
Primary CompletionFeb 2020
TodayJul 2026
First PostedSep 21, 2017
Enrollment StartDec 5, 2013
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 8.8 years ago
Interventions
Pure PRP IIcombination
The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
PureBMCcombination
The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.